Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Efficacy and safety analysis of CAR-T cell therapy in relapsed/refractory diffuse large B-cell lymphoma after failure of bispecific antibody treatment

View Full Paper
Ask AI
Bookmark
Share

Authors

JCJia Cong

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows CAR-T therapy achieves 100% response in lymphoma patients, suggesting effective salvage strategy after bispecific antibody failure.

Key Points

  • CAR-T therapy demonstrated an overall response rate of 100% in relapsed/refractory diffuse large B-cell lymphoma patients.
  • Median progression-free survival and overall survival rates remain uncalculated, emphasizing the need for further follow-up.
  • Adverse events included cytokine release syndrome and hematologic toxicities like neutropenia and anemia, primarily manageable.
  • The research supports CAR-T as a promising salvage therapy for individuals with poor outcomes after bispecific antibody treatment.

Cite This Study

Jia Cong (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d59fhttps://doi.org/10.1182/blood-2025-1941
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clinical and pathological features of patients with large B-cell lymphoma relapsing after CAR T-cell therapy2025 · 1 citations
  2. 2Efficacy and safety of CAR-T cell therapy versus bispecific antibodies in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: A single-arm meta-analysis2025
  3. 3Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma2025
  4. 4CAR-T Cell Therapy Versus Salvage Chemotherapy in Relapsed/Refractory DLBCL: A Systematic Review and Meta-Analysis Integrating Radiologic, Laboratory, and Histopathologic Correlates.2026
  5. 5CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations